European Approval of Vitravene Triggers $2.5 MM Milestone for Isis
European Approval of Vitravene Triggers $2.5 MM Milestone for Isis
About this item
Full title
European Approval of Vitravene Triggers $2.5 MM Milestone for Isis
Publisher
New York: PR Newswire Association LLC
Journal title
PR Newswire, 1999, p.1
Language
English
Formats
Publication information
Publisher
New York: PR Newswire Association LLC
Subjects
More information
Scope and Contents
Contents
CARLSBAD, Calif., Aug. 4 /PRNewswire/ -- Vitravene(TM), the antiviral drug developed by Isis Pharmaceuticals (Nasdaq: ISIP) and marketed by CIBAVision, has been approved by European regulatory authorities. Isis and CIBAVision Corporation, the eye care unit of Novartis AG, a leading world sciences company have been informed that a Community Marketin...
Alternative Titles
Full title
European Approval of Vitravene Triggers $2.5 MM Milestone for Isis
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_449604160
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_449604160
How to access this item
Log in as a Library member
